Abstract
Enriched lymphocytes from patients with primary hepatocellular carcinoma showed considerably reduced natural cytotoxicity against two established hepatoma cell lines and against the myelogenous derived cell line K562, as compared to lymphocytes from normal volunteers or from patients with various nonmalignant liver diseases. The serum of hepatoma patients did not effect normal or patient NK cell activity. When lymphocytes from patients or controls were treated for three hours with human leukocyte interferon, NK cell cell activity was significantly improved. Levamisole did not produce a significant increase in normal NK cytotoxicity but did improve the killing of lymphocytes from patients with hepatocellular carcinoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
